Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

3

Comparison of Lamivudine-induced HBsAg Loss rate according to age in children with chronic hepatitis B

Jung Mi Kim , Byung Ho Choe , Mi Ae Chu , Seung Man Cho

Clin Mol Hepatol. 2009;15(2):168-178. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.168

View: 4460 Download: 44 Crossref: 3

Etiology and Clinical Consequence of Spontaneous Acute Exacerbation of Chronic Hepatitis B

Myung Jong Chae , Byung Ho Kim , Kyung Hwan Jeong , Nam Hoon Kim , Seok Ho Dong , Hyo Jong Kim , Young Woon Chang , Joung Il Lee , Rin Chang

Clin Mol Hepatol. 2004;10(2):99-107. Published online January 1, 1970

View: 2306 Download: 32

Pretreatment ALT Level and Histologic Activity as Predictors of HBeAg Loss in Lamivudine Treatment for Chronic Hepatitis B

Young Oh Kweon, M.D. and Kyung Hee Kang, M.D.

Clin Mol Hepatol. 2004;10(1):31-41. Published online January 1, 1970

View: 2595 Download: 14

Long - term Efficacy and Durability of Lamivudine Therapy in Patients with Chronic Hepatitis B

Chae Yoon Chon,Sang Hoon Ahn,Kwang Hyub Han,Young Myoung Moon,Sung Pil Hong,Yong Han Paik,Byung Soo Moon

Clin Mol Hepatol. 2001;7(4):423-431. Published online January 1, 1970

View: 2385 Download: 14

The Effect of Long-term Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus

Kwang Hyub Han, M.D., Jin Suk Kim, M.D., Hyo Young Chung Sang Hoon Ahn, M.D., Yong Han Paik, M.D., Kwan Sik Lee, M.D., Chae Yoon Chon, M.D. and Young Myoung Moon, M.D.

Clin Mol Hepatol. 1999;5(2):97-104. Published online January 1, 2000

View: 2413 Download: 14

1 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5413	MAFLD: How is it different from NAFLD?
Viewed By 5222	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5101	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search